Navigation Links
Michael J. Fox Foundation Awards $3.8 Million To Drive Nine Industry Partnerships For Pre-Clinical Parkinson's Drug Development
Date:7/21/2009

NEW YORK, July 21 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research has awarded research teams at nine biotech and pharmaceutical companies a total of $3.8 million for pre-clinical Parkinson's drug development projects. Funded investigations aim to push forward novel neuroprotective and improved symptomatic therapies as well as new strategies for addressing complications of treatment.

While MJFF accepts applications from industry under all of its programs, the Therapeutics Development Initiative (TDI) - first launched in 2006 - is the Foundation's only industry-exclusive funding stream. It is a key element of MJFF's strategy to 'de-risk' preclinical PD research for biotech and pharmaceutical companies, thus expanding industry investment in Parkinson's therapeutic development and helping push the most promising research to the next stage.

Projects selected for funding are listed below. Detailed information, including grant abstracts and researcher bios, is available on the Foundation's Searchable Database of Funded Grants. As with all MJFF grants, full funding is contingent on the achievement of predetermined, specific milestones and on researchers' agreement to make the results of their work available to the Parkinson's research community.

Neuroprotective Approaches

Pharmacodynamics of ReS9-S7, a first-in-class, disease-modifying drug candidate for treatment of Parkinson's disease

Gerard Griffioen, PhD, NV reMYND, Leuven, Belgium

Exploring curcumin and curcumin derivatives as putative epigenetic targets of histone deacetylase (HDAC) inhibition in Parkinson's disease

Lawrence Helson, MD, Sign Path Pharma, Inc., Quakertown, Pennsylvania

Assessment of the therapeutic efficacy of progranulin in a sub-chronic animal model of Parkinson's disease

Denis Kay, PhD, Neurodyn, Inc., Charlottetown, Prince Edward Island, Canada

Validation of LRRK2 as a drug target for treatment of Parkinson's disease using antisense technology

Alejandro Lloret, PhD, Isis Pharmaceuticals, Inc., Carlsbad, California

Optimizing lead series of small molecule inhibitors of LRRK2 to deliver tool compounds and clinical development candidates

Alastair D. Reith, PhD, GlaxoSmithKline, United Kingdom

A novel approach to characterize the distribution of a potentially therapeutic dominant-negative inhibitor of tumor necrosis factor in pre-clinical models of PD, and predict the scalability for an effective delivery of therapy in the human brain

Lisa Lynn Shafer, PhD, Medtronic Neuromodulation, Minneapolis, Minnesota

Pre-clinical development of a Parkinson's disease therapy using a glucagon-like peptide (GLP-1) receptor agonist

Kevin Tomaselli, PhD, Amylin Pharmaceuticals, Inc., San Diego, California

Symptomatic Approaches/Complications of Treatment

Effect of novel neuronal nicotonic receptor compounds on treatment of levodopa-induced dyskinesia in Parkinson's disease

Kristen Jordan, PhD, Targacept, Winston-Salem, North Carolina

Optimization of MOR antagonists for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease

Patrick Little, PhD, Adolor Corporation, Exton, Pennsylvania

TDI is launched bi-annually with applications accepted each spring and fall. It has been enthusiastically received by industry researchers. To date the Foundation has awarded $16.5 million total for 33 industry-led projects under the initiative.

About The Michael J. Fox Foundation

The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's today. To date, the Foundation has funded $149 million in research. For more information on TDI and the Foundation's industry strategy, please visit www.michaeljfox.org/industry.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Michael Moores SiCKO Becomes the Third Highest Grossing Documentary of All Time Surpassing An Inconvenient Truth
2. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
3. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
4. Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director
5. Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008
6. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
7. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
8. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
9. Actress Jenifer Lewis, Authors Dr. Michael Eric Dyson and Susan Taylor Among Featured Speakers for Senator Hughes Behavioral Mental Health Summit
10. Michael J. Fox Foundation Launches Rapid Response Innovation Awards 2008 Following Strong Inaugural Year Response
11. Siemens Medical Solutions Michael Long Recognized as one of Computerworlds 2008 Premier 100 IT Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Moore Insurance, an eastern Texas ... to asset protection and financial planning services, is teaming up with the For ... of children with cancer and other chronic diseases. , The For A Day ...
(Date:6/22/2017)... ... 22, 2017 , ... United Benefit Advisors (UBA), the nation’s ... as its newest Partner Firm. Headquartered in Coconut Creek, Florida, Whipple & Company ... optimized benefit packages that strengthen the relationship between employer and employee. , “We ...
(Date:6/22/2017)... ... June 23, 2017 , ... Despite its pervasiveness, many ... reviews available that integrate basic science with clinical practice. Now, however, a timely review ... providing clinicians with insight into the etiology of NeuP and educating preclinical scientists on ...
(Date:6/22/2017)... ... June 22, 2017 , ... A June 12 article in ... about an apparent lack of oral hygiene by an aged parent who had recently ... matters, suggests a number of steps, including scheduling a dentist visit. Northridge Dental Works, ...
(Date:6/20/2017)... ... June 20, 2017 , ... Connance, a leading provider ... present how predictive analytics drive reimbursement optimization, with a focus on denial management ... , “The traditional approach to denied and underpaid claims leaves money on ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... N.Y. , May 22, 2017  Lilac ... treatment Gene-Eden-VIR/Novirin, announces the launch of a ... English, the results of a clinical study that ... year treatment with Gene-Eden-VIR/Novirin in individuals suffering from ... to note that there are no other treatments ...
(Date:5/18/2017)...  Two Bayer U.S. Pharmaceutical leaders received top awards ... 28 th Woman of the Year ... longstanding mission of furthering the advancement and impact of ... Cindy Powell-Steffen , senior director of brand activation and ... Libby Howe , a regional business manager for New ...
(Date:5/15/2017)...  Amy Baxter MD, chief executive officer and founder ... relief, was awarded a 2017 Top 40 Healthcare Transformer ... at the MM&M Top 40 Healthcare Transformers dinner and ... on May 10, 2017. The dinner followed a full-day ... the pill."  "Innovation goes beyond invention," noted ...
Breaking Medicine Technology: